Microbot Medical Inc.
175 Derby St., 27/1
About Microbot Medical Inc.Microbot was founded in 2010 and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
Founders: Harel Gadot, Moshe Shoham, Yossi Bornstein
CEO: Harel Gadot
COO: Hezi Himelfarb
CFO: David Ben Naim
FOLLOW MICROBOT MEDICAL:
Tweets by Microbot
95 articles about Microbot Medical Inc.
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
Microbot Medical Inc., developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption application with the US Food and Drug Administration.
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Microbot Medical Inc. today announced that following the recent positive results of its pivotal GLP Pre-Clinical Study, and to support its anticipated IDE submission to commence its first in human clinical trial, the Company added a US- based Clinical Research Associate (CRA).
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
Microbot Medical Inc. announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
Microbot Medical Inc., developer of the innovative LIBERTY® Endovascular Robotic Surgical System, announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer, effective December 1, 2023.
Microbot Medical Inc., the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announced it had been granted a registered trademark from the US Patent and Trademark Office.
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
Microbot Medical Inc., developer of the innovative LIBERTY® Robotic Surgical System, announces additional updates regarding positive outcomes of its previously announced pivotal pre-clinical study using the LIBERTY Robotic Surgical System.
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
Microbot Medical Inc., developer of the innovative LIBERTY® Robotic Surgical System, announces it has received confirmation for the commencement of the process to support its future CE Mark approval, and to ultimately allow the Company to market the LIBERTY® Robotic Surgical System in Europe as well as other regions who accept the CE Mark.
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study.
Microbot Medical Inc. announced its partnership with a Contract Research Organization in the U.S. This is an additional step in the preparations to the commencement of the Company's planned upcoming clinical trial.
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
Microbot Medical Inc. announces another step in its commitment to advance the commercialization processes of LIBERTY® with the signing of a manufacturing agreement with B.Y. Medimor Ltd.
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Microbot Medical Inc., the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, announces the expansion of its global team of experts supporting the Company as scientific advisory board members, with Francois H. Cornelis, MD, PhD joining Microbot's SAB.
Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board
Microbot Medical Inc. announced that Irene Bargellini, M.D., an interventional radiologist and Chair of the Diagnostic and Interventional Radiology Department at Candiolo Cancer Institute in Turin, Italy, has joined the Company’s Scientific Advisory Board.
Microbot Medical Inc. announced the successful completion of an extended pre-clinical study held by leading key opinion leaders at a New York-based research lab.
Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings
Microbot Medical Inc. announced that it closed its previously announced registered direct offering for the purchase and sale of 624,618 shares of the Company’s common stock at a purchase price of $3.25 per share of common stock priced at-the-market under Nasdaq rules.
Microbot Medical Inc. announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY Robotic Surgical System.
Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe
Microbot Medical Inc. is encouraged by the continued participation and level of enthusiasm being demonstrated by the Key Opinion Leaders globally who are using the LIBERTY® Robotic Surgical System during the Company’s pre-clinical animal studies.
Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System
Microbot Medical Inc. (Nasdaq: MBOT) announced it has received a grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 1.62 million, which based on a recent exchange rate to the U.S. dollar, would be approximately $440,000, to further support the development of the Company’s manufacturing process of its flagship robotic surgical system, the LIBERTY®.
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process
Microbot Medical Inc. announces that an additional milestone was achieved when medical professionals experienced the Company's LIBERTY Robotic Surgical System as part of a formative study.
Lahey Hospital & Medical Center Agrees to become One of the U.S. Sites for the LIBERTY® Robotic System’s First Human Trial
Microbot Medical Inc. announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system.